AVANIR to Present at The Wall Street Analyst Forum Conference
AVANIR Pharmaceuticals (NASDAQ: AVNR) today announced that Keith Katkin, President and Chief Executive Officer, will present at The Wall Street Analyst Forum 19th Annual Analyst Conference on Wednesday, September 10 at 11:10 a.m. Eastern time (8:10 a.m. Pacific time). This conference will be held at The University Club in New York. The Wall Street Analyst Forum sponsors annual investor conferences that provide a forum for participating publicly traded mid and small cap companies to meet with key buy/sell side analysts and portfolio managers from money management firms. For more information visit http://www.analyst-conference.com/.
A live audio and slide webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary audio software. An updated version of the Company's corporate presentation was posted to www.avanir.com today. An archive of Mr. Katkin's presentation at The Wall Street Analyst Forum Conference will be available on the Company's website for 30 days.
AVANIR Pharmaceuticals is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and is the subject of an approvable letter from the U.S. Food and Drug Administration (FDA) for that indication. The Company has initiated a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the FDA utilizing a new lower quinidine dose formulation of Zenvia intended to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. Additionally, in April 2007 AVANIR announced meeting all primary endpoints in a Phase III clinical trial with Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. In May 2008 the Company released top-line results of a formal pharmacokinetic (PK) study that identified alternative lower-dose quinidine formulations of Zenvia for DPN pain intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0
AVANIR Investor Contacts
Eric Benevich or Brenna Mullen, 949-389-6700
Sep 03, 2008